Compare EPR & ADMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | EPR | ADMA |
|---|---|---|
| Founded | 1997 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.4B | 4.1B |
| IPO Year | 1997 | N/A |
| Metric | EPR | ADMA |
|---|---|---|
| Price | $50.15 | $19.78 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 11 | 2 |
| Target Price | ★ $57.06 | $28.50 |
| AVG Volume (30 Days) | 609.7K | ★ 2.9M |
| Earning Date | 10-29-2025 | 11-05-2025 |
| Dividend Yield | ★ 7.07% | N/A |
| EPS Growth | N/A | ★ 205.35 |
| EPS | ★ 2.29 | 0.86 |
| Revenue | ★ $707,150,000.00 | $488,559,000.00 |
| Revenue This Year | $5.11 | $22.19 |
| Revenue Next Year | $2.70 | $24.33 |
| P/E Ratio | ★ $21.91 | $23.11 |
| Revenue Growth | 3.73 | ★ 27.63 |
| 52 Week Low | $41.75 | $13.50 |
| 52 Week High | $61.24 | $25.67 |
| Indicator | EPR | ADMA |
|---|---|---|
| Relative Strength Index (RSI) | 38.11 | 66.02 |
| Support Level | $49.41 | $19.13 |
| Resistance Level | $51.80 | $20.22 |
| Average True Range (ATR) | 0.94 | 0.73 |
| MACD | -0.15 | 0.05 |
| Stochastic Oscillator | 20.14 | 79.44 |
EPR Properties is a real estate investment trust that focuses on underwriting experiential property investments on key industry and property cash flow criteria, and the credit metrics of tenants and customers. The company invests in two property segments: Experiential, including theaters, family entertainment centers, ski resorts, and other attractions; and Education, including early childhood education centers and private school properties. The Company's business is focused on Experiential real estate. The majority of revenue comes from the Experiential sector.
ADMA Biologics Inc is an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases. The segments of the company are ADMA BioManufacturing which generates maximum revenue and Plasma Collection Centres, and corporate segment. The company sells plasma-derived intermediate fractions to certain customers, which are generated as part of its FDA-approved manufacturing process for IG and IVIG products. It also provides laboratory contracting services to certain customers and anticipates providing contract filling, labeling and packing services. The company derives maximum revenue from United States.